Cyclerion Therapeutics Inc

CYCN NASDAQ
8.83
-0.33
-3.60%
After Hours: 8.83 0 0.00% 16:00 08/23 EDT
Open
9.10
Prev Close
9.16
High
9.64
Low
8.42
Volume
40.67K
Avg Vol (3M)
169.84K
52 Week High
22.85
52 Week Low
7.83
% Turnover
0.15%
Market Cap
242.13M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Cyclerion Therapeutics Inc CYCN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for serious and orphan diseases. The Company develops guanylate cyclase (sGC) stimulators. The Company’s portfolio includes five sGC stimulator programs: olinciguat, praliciguat, IW-6463 and two organ-targeted programs. Olinciguat is an oral, once-daily vascular sGC stimulator for patients suffering from sickle cell disease. Olinciguat is in Phase II trial. Praliciguat is an oral, once-daily systemic sGC stimulator for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy. Praliciguat is in two separate Phase II trials. IW-6463 is a central nervous system-penetrant oral sGC stimulator. IW-6463 is in a Phase I and is designed to treat serious and orphan neurodegenerative diseases. Its two organ-targeted programs are designed to address serious and orphan diseases of the liver and lung.
MORE >

Recently

Name
Price
%Change